Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease-Reference-Cited by-同舟云学术

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease

Published:2024-08-26 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Stork Martin^ORCID,Ondrouskova Eva^ORCID,Bohunova Michaela,Boichuk Ivanna,Fric Dominik,Adam Zdenek,Krejci Marta,Sandecka Viera,Knechtova Zdenka,Radova Lenka,Jelinkova Zuzana,Adlerova Tatana,Krticka Milan,Nekuda Vladimir,Borsky Marek,Sevcikova Sabina^ORCID,Jarosova Marie,Pour Ludek

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-01131-6.pdf

Reference12 articles.

1. Neupane K, Fortuna GG, Dahal R, Schmidt TM, Fonseca R, Chakraborty R, et al. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J. 2024;14:20–30. https://doi.org/10.1038/s41408-024-00985-0

2. Jiménez-Segura R, Rosiñol L, Cibeira MT, Fernández de Larrea C, Tovar N, Rodríguez-Lobato LG, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. 2022;12:135.

3. Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;36:32–9. https://doi.org/10.1016/j.blre.2019.04.002

4. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. Blood. 2022;140:1229–53. https://doi.org/10.1182/blood.2022015851

5. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 2016;97:93–100.